I-Abrocitinib iyingqamuzana yomlomo, encane, i-Janus kinase (JAK) 1 inhibitor ekuthuthukisweni kokwelashwa kwabantu abadala kanye nentsha ene-atopic dermatitis emaphakathi kuya kokuqina.

I-Abrocitinib iyaphenywa esivivinyweni somtholampilo i-NCT03796676 (JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis).

I-Abrocitinib okwamanje ithuthukiswa yi-Pfizer yokwelapha i-atopic dermatitis (eczema). I-Janus kinase 1 (JAK1) inhibitor yophenyo yomlomo kanye ngosuku.

I-atopic dermatitis (AD) yisifo sesikhumba esiyinkimbinkimbi, esingelapheki, esivuvukalayo esibonakala ngokuluma, ukulunywa okukhulu, nezilonda ze-eczematous ezithinta cishe u-25% wezingane kanye no-2% kuya ku-3% wabantu abadala emhlabeni jikelele. I-Abrocitinib iyi-inhibitor ekhethiwe ye-enzyme ye-Janus kinase-1 (JAK1) evimbela inqubo yokuvuvukala. Ngakho-ke, sasihlose ukuhlola ukusebenza kahle nokuphepha kwe-abrocitinib ku-AD emaphakathi ukuya kobukhali.

I-Abrocitinib kumthamo 100 mg noma 200 mg umuthi osebenzayo, obekezelelwa kahle, futhi othembisayo ekwelapheni iziguli ezine-atopic dermatitis emaphakathi ukuya kokuqina. Nokho, ukuhlaziya kuthande ukusebenza kahle kwe-abrocitinib 200 mg ngaphezu kuka-100 mg, kodwa imiphumela engemihle efana nesicanucanu nekhanda elibuhlungu kungenzeka kwenzeke kakhulu nge-200 mg.